2019 ESC Congress Symposium Lectures & Videos
Resverlogix through an unrestricted grant, is supporting an educational symposium during the ESC Congress 2019 titled: "Epigenetics: A new pathway to tackle residual risk?"
Saturday, August 31, 2019: 15:30 – 16:30 hrs (Paris, France).
- to summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- to understand the origin of the high residual cardiovascular risk in patients with diabetes and CVD
- to review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- to update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
Introduction - Ulf Landmesser, MD, Berlin, Germany
Challenges in targeting residual risk in diabetic patients, post ACS - Peter Libby, MD, Boston, USA
BET inhibition, an epigenetic pathway: how could BET inhibition modulate atherothrombotic risk - Wouter Jukema, MD, Leiden, the Netherlands
Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition? - Kausik Ray, MD, London, United Kingdom
Video Presentations & Symposium Highlights can be accessed HERE approximately two months following the live event.